Lin Youdong, Wang Xiaoting, Yu Yinghao, Liu Wei, Xie Feilai, Ouyang Xuenong, Huang Qiaojia
Department of Experimental Medicine, Fuzhou General Hospital, Fuzong Clinical College of Fujian Medical University, Fuzhou, Fujian 350025, P.R. China.
Department of Pathology, Fuzhou General Hospital, Fuzong Clinical College of Fujian Medical University, Fuzhou, Fujian 350025, P.R. China.
Oncol Lett. 2017 Dec;14(6):7473-7482. doi: 10.3892/ol.2017.7107. Epub 2017 Sep 29.
Cyclin-dependent kinase inhibitor 1A (CDKN1A) is an important cell cycleregulator, and has been identified to exhibit aberrant expression in various types of cancer tissues. However, the association between CDKN1A expression level and prognosis in patients with resected gastric adenocarcinoma (RGA) requires additional elucidation. In the present study, the CDKN1A expression profile in RGA tissues obtained from 217 patients were analyzed using immunohistochemistry. Its prognostic significance was evaluated by using the χ test, Kaplan-Meier curves and the log-rank test, and a multivariate Cox model analysis, during a median follow-up time of 51 months. The results demonstrated that CDKN1A expression was significantly correlated with lymph node metastasis (LNM; P=0.001), recurrence (P<0.001) and overall survival (OS; P<0.001). In addition, the recurrence-free survival (RFS) and OS times were significantly shorter in patients with low CDKN1A expression compared with those with high CDKN1A expression (RFS, 20 months vs. 69 months, P<0.001; and OS, 32 months vs. 70 months, P<0.001, respectively). Multivariate analysis additionally confirmed that low CDKN1A expression was significantly correlated with an increased risk of LNM (P=0.001), recurrence (P<0.001) and mortality (P<0.001). Therefore, these data suggest that low expression of CDKN1A has independent prognostic significance indicative of tumor progression and poor survival in patients with RGA. Evaluation of CDKN1A expression may assist in determining prognosis in patients with RGA.
细胞周期蛋白依赖性激酶抑制剂1A（CDKN1A）是一种重要的细胞周期调节因子，已被证实在各种类型的癌组织中存在异常表达。然而，CDKN1A表达水平与接受手术切除的胃腺癌（RGA）患者预后之间的关联仍需进一步阐明。在本研究中，采用免疫组织化学方法分析了217例RGA患者的RGA组织中CDKN1A的表达谱。在中位随访时间51个月期间，通过χ检验、Kaplan-Meier曲线和对数秩检验以及多变量Cox模型分析评估其预后意义。结果表明，CDKN1A表达与淋巴结转移（LNM；P=0.001）、复发（P<0.001）和总生存期（OS；P<0.001）显著相关。此外，与CDKN1A高表达患者相比，CDKN1A低表达患者的无复发生存期（RFS）和OS时间显著缩短（RFS分别为20个月和69个月，P<0.001；OS分别为32个月和70个月，P<0.001）。多变量分析进一步证实，CDKN1A低表达与LNM风险增加（P=0.001）、复发（P<0.001）和死亡率（P<0.001）显著相关。因此，这些数据表明，CDKN1A低表达具有独立的预后意义，提示RGA患者肿瘤进展和生存不良。评估CDKN1A表达可能有助于确定RGA患者的预后。
